PR84513

VISBEK, Germany, June 24, 2020 /PRNewswire=KYODO JBN/ --

IgNova announced today that it has filed a patent application covering the use

of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a

biopharmaceutical R&D start up, researches technology based on specific egg

immunoglobulins (IgY).  

The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus

when it enters the mouth or nose and, therefore, inhibiting the infection

process. IgNova's technology offers a safe, economical, and unlimited source of

polyclonal antibodies to control SARS-CoV-2.

The IgY antibody technology has a wide range of applications such as chewable

tablets, sprays, or mouthwash, offering instant protection against SARS-CoV-2.

Additional applications, such as IgY-coated air filters and masks, could

potentially support medical professionals and other at-risk professions. With

antigen and antibody production as well as specific applications included in

the patent, IgNova envisions an exhaustive IgY technology response to

COVID-19.  

"We are at the final research stage," says Michael Gerrits, IgNova Managing

Director, "working closely with scientific institutions and potential strategic

partners to bring the technology to market. We have started initial testing

with the objective to allow our partners to introduce IgNova technology based

products to market in Q4 2020."

IgNova's patent is based on proprietary IgY technology, a process that involves

immunizing chickens against target pathogens, extracting antibodies from eggs.

IgY technology was developed in the 1980s to help control dental caries. In

Japan, the technology is widely used both in food and human health applications.

"Early research looks promising," says IgNova Managing Director Tonchy

Ugrinovic. "With the right scientific and production partners, IgNova targets a

mass-marketable solution in Q4 of this year 2020."

About IgNova

Founded in 2013, IgNova is a biopharmaceutical R&D start up that drives IgY

technology innovation in accordance with stringent quality management and

design control standards. At production sites in the US, Japan, and Europe,

cutting-edge health and safety solutions are developed in close collaboration

with industry partners.

Contact

Pia Becker  

Tel: +49 4445 9868174  

Mobile: +49 151 10464268  

Email: contact@ignova.com

Source: IgNova GmbH